Schering Sees PEG-Intron Market Share Begin To Stabilize
This article was originally published in The Pink Sheet Daily
Executive Summary
U.S. market share for Schering-Plough's hepatitis C treatment PEG-Intron (pegylated interferon) is starting to stabilize, Global Pharmaceutical President Carrie Cox said.
You may also be interested in...
Roche Pegasys sBLA Filing For Hepatitis B Could Receive Priority Review
Roche announced simultaneous U.S. and European submissions July 21; six-month review would set user fee date at mid-January. Roche is likely to highlight superiority to GlaxoSmithKline’s Epivir-HBV and efficacy in HBeAg-negative patients in promotions.
Roche Pegasys sBLA Filing For Hepatitis B Could Receive Priority Review
Roche announced simultaneous U.S. and European submissions July 21; six-month review would set user fee date at mid-January. Roche is likely to highlight superiority to GlaxoSmithKline’s Epivir-HBV and efficacy in HBeAg-negative patients in promotions.
Schering Generic Ribavirin Carries PEG-Intron Indication; Valeant Will Receive Royalties
Schering generic launches April 8, two days after FDA clears Three Rivers’ and Sandoz’ ribavirin ANDAs. All generics are expected to be priced at a 10% discount to Schering’s Rebetol.